Is there a generic version of Revumenib that can be purchased legally?

Revumenib (Revumenib) is an innovative and selective mixed lineage leukemia (MLL1/KMT2A) inhibitor, mainly used to treat patients with Patients with relapsed or refractory acute myeloid leukemia (AML) with KMT2Arearrangement or NPM1 mutation. The drug was developed by Syndax Pharmaceuticals. It is a targeted therapy with a new mechanism. It is currently only available in the form of specific projects (such as clinical trials or accelerated approval) in a few regions such as the United States, so it is still in the early stages of marketing globally.

As of now (2025), there are no legal generics of Revimenib circulating on the market. Since the drug is a new molecular entity and is still within the global patent protection period (the patent period is expected to last until around 2035), drug regulatory agencies in most countries and regions have not yet approved any generic versions. Even if there may be products labeled as "imitation" in some areas, most of them are unofficial sources of drugs without formal review and certification. There are risks of unknown ingredients and difficult to guarantee quality. Patients are not recommended to buy and use them rashly.

In terms of legal purchase channels, currently Mainland China has not approved the marketing of Revimenib, nor has it been included in any special medication items. Therefore, if domestic patients really need to use the drug, they can usually only obtain it through the following methods: first, participating in clinical trial projects at overseas or cooperative hospitals; second, applying for "single drug special approval" import through a registered cross-border medical service platform. Such operations must comply with the relevant provisions of the "Drug Administration Law" and be conducted under the guidance of a doctor to ensure that the source and use of the drug are legal and compliant.

In short, although Revimenib has shown promising results in the targeted treatment of AML, as it is still an original drug under investigation or an early-stage drug on the market, there are currently no legal generic drugs available for sale. If patients consider using it, they should carefully evaluate the risks and the legality of the channel, and do not purchase "generic drugs" of unknown origin through informal platforms to avoid affecting their condition or causing adverse reactions. In clinical practice, it is recommended that professional hematologists evaluate the treatment plan and coordinate formal medical resources for medication application or treatment referral.

Reference materials:https://www.drugs.com/